Choksi Laboratories Schedules Board Meeting on May 25, 2026 to Approve Q4 and Full-Year FY26 Audited Results

1 min read     Updated on 16 May 2026, 12:33 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Choksi Laboratories has scheduled its 02/2026-27 Board of Directors meeting for May 25, 2026, at 02:30 P.M. at its registered office in Indore, to consider and approve standalone audited financial results for Q4 and the year ended March 31, 2026. The intimation was filed pursuant to Regulation 29(1) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The trading window, closed since April 1, 2026, will reopen 48 hours after the declaration of the audited results. The filing was submitted by Company Secretary and Compliance Officer Prakhar Dubey on May 16, 2026.

powered bylight_fuzz_icon
40460596

*this image is generated using AI for illustrative purposes only.

Choksi Laboratories has notified BSE Limited of its forthcoming Board of Directors meeting, filed in compliance with Regulation 29(1) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The meeting, designated as the 02/2026-27 board meeting, has been scheduled for Monday, May 25, 2026, at 02:30 P.M., to be held at the company's registered office located at Survey No. 9/1, Near Tulsiyana Industrial Park, Kumerdi, Indore, 453555 (M.P.).

Board Meeting Agenda

The board meeting has been convened to deliberate on key financial and administrative matters. The following items are on the agenda:

Agenda Item: Details
Primary Business: Consider and approve standalone audited financial results for Q4 and year ended March 31, 2026
Additional Business: Any other item with permission of the Chairman and consent of majority of Directors present, including at least one independent Director

The company has also confirmed that the required disclosures will be submitted in both XBRL mode (using the excel template provided by the Exchange) and PDF mode within the prescribed time limit.

Trading Window Closure

In continuation of an earlier disclosure dated March 26, 2026, Choksi Laboratories has reiterated that the trading window for dealing in the securities of the company has been closed with effect from April 1, 2026, pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended.

The trading window will reopen 48 hours after the declaration of the audited financial results for the quarter and year ended March 31, 2026. This restriction applies to all designated persons, their immediate relatives, and all connected persons covered under the aforesaid code.

Regulatory Filing Details

The intimation was signed and submitted by Prakhar Dubey, Company Secretary and Compliance Officer, on May 16, 2026, and has been addressed to the Corporate Relationship Department of BSE Limited. The company has requested BSE to take the information on record and disseminate it on the BSE website.

Historical Stock Returns for Choksi Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-5.62%-0.60%+0.66%-29.31%-15.42%+903.04%

How might Choksi Laboratories' Q4 and full-year FY2026 financial results compare to its previous year's performance, and what growth trajectory could investors expect?

Will the board meeting on May 25, 2026 include any discussions on dividend declarations or capital allocation strategies beyond the financial results approval?

How could the trading window reopening 48 hours after the results announcement impact short-term price volatility in Choksi Laboratories' stock?

Choksi Laboratories Completes Postal Ballot with 99.86% Approval for Independent Director Appointment

3 min read     Updated on 28 Apr 2026, 12:33 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Choksi Laboratories Limited successfully completed its postal ballot voting process on April 26, 2026, with shareholders approving the appointment of Mr. Ritik Pavecha as Non-Executive Independent Director with 99.86% votes in favor. The remote e-voting conducted through CDSL platform from March 28 to April 26, 2026, saw 20.87% voter turnout with 1453636 votes polled, of which 1451635 supported the resolution and only 2001 opposed. CS Surabhi Agrawal served as scrutinizer, confirming compliance with Companies Act, 2013 and SEBI regulations.

powered bylight_fuzz_icon
38905280

*this image is generated using AI for illustrative purposes only.

Choksi Laboratories Limited has successfully concluded its postal ballot voting process on April 26, 2026, with shareholders demonstrating strong support for the company's governance initiatives. The pharmaceutical company announced the completion of remote e-voting for special resolutions under Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Postal Ballot Process Details

The remote e-voting process was conducted over a month-long period, providing shareholders ample opportunity to participate in the decision-making process. The voting timeline and key parameters are outlined below:

Parameter Details
Notice Date Saturday, February 07, 2026
Cut-off Date Friday, March 20, 2026
Voting Start Saturday, March 28, 2026 at 09:00 AM IST
Voting End Sunday, April 26, 2026 at 05:00 PM IST
Total Shareholders 4070
Resolutions Passed 01 (One)

Voting Results and Shareholder Participation

The special resolution regarding the appointment of Mr. Ritik Pavecha (DIN: 08790431) as Non-Executive Independent Director received overwhelming approval from shareholders. The voting results demonstrate strong confidence in the proposed appointment:

Category Shares Held Votes Polled Votes in Favor Votes Against Approval Rate
Promoter Group 2192754 1444392 1444392 0 100.00%
Public Non-Institutions 4772509 9244 7243 2001 78.35%
Total 6965263 1453636 1451635 2001 99.86%

The overall voter turnout stood at 20.87% of the total eligible shares, with 99.86% of polled votes supporting the resolution. Only 2001 votes were cast against the proposal, representing merely 0.14% of the total votes polled. The promoter/promoter group confirmed they were not interested in this agenda/resolution.

Scrutinizer's Report and Compliance

CS Surabhi Agrawal from Surabhi Agrawal & Associates served as the appointed scrutinizer for the postal ballot process. The scrutinizer's report confirmed the fair and transparent conduct of the remote e-voting process through the CDSL platform. The report validated that all procedural requirements under Sections 108 and 110 of the Companies Act, 2013, and relevant SEBI regulations were duly followed.

The scrutinizer emphasized that the voting process was conducted in compliance with Companies Act, 2013 and associated rules, SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, MCA circulars and guidelines, and electronic voting system security frameworks. The votes were unblocked on April 26, 2026 at 05:00 PM after the conclusion of the meeting and witnessed by Ms. Vaishnavi Dhone and Ms. Anishi Dammani, who are not in the employment of the company.

Board Appointment Details

The approved resolution pertains to the appointment of Mr. Ritik Pavecha, bearing Director Identification Number 08790431, as a Non-Executive Independent Director of the company. This appointment aligns with corporate governance best practices and regulatory requirements for board composition. The resolution was classified as a special resolution, requiring higher approval thresholds, which the company successfully achieved.

Corporate Communication

Prakhar Dubey, Company Secretary and Compliance Officer, signed the official communication to BSE Limited on April 28, 2026, formally notifying the stock exchange of the voting results. The company maintains its registered office at Office No. 102, 02nd Floor, Mishika Tower, Sneh Nagar, Indore, while its corporate office and central laboratory are located at Survey No 9/1, Near Tulsiyana Industrial Park, Gram Kumerdi, Indore. The scrutinizer's report was dated April 27, 2026, with UDIN: F013816H000211519.

Historical Stock Returns for Choksi Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-5.62%-0.60%+0.66%-29.31%-15.42%+903.04%

What strategic initiatives or expansion plans might Mr. Ritik Pavecha's appointment as Independent Director enable for Choksi Laboratories?

How could the enhanced board composition impact Choksi Laboratories' ability to secure new partnerships or regulatory approvals in the pharmaceutical sector?

Will this governance strengthening position Choksi Laboratories for potential fundraising activities or IPO preparations in the near future?

More News on Choksi Laboratories

1 Year Returns:-15.42%